The evolution in registration of clinical trials: a chronicle of the historical calls and current initiatives promoting transparency Claudia PansieriChiara PandolfiniMaurizio Bonati Review 05 August 2015 Pages: 1159 - 1164
Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension Anna SandqvistDan HenrohnGerhard Wikström Clinical Trial 05 August 2015 Pages: 1165 - 1173
Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects Dave SinghLeonard SiewLisa Tan Clinical Trial Open access 13 August 2015 Pages: 1175 - 1184
Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance James H. HoGeorge P. BaileyDavid M. Wood Pharmacodynamics 22 July 2015 Pages: 1185 - 1196
Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects Heedoo YooTimo IirolaWilliam J. Jusko Pharmacodynamics 02 August 2015 Pages: 1197 - 1207
Model-based meta-analysis of the effects of non-selective and α1-selective GABAA receptor agonists in healthy volunteers Yu-Peng RenRu-Jia XieWei Lu Pharmacodynamics 11 August 2015 Pages: 1209 - 1221
Lower CYP2C9 activity in Turkish patients with Behçet’s disease compared to healthy subjects: a down-regulation due to inflammation? Mustafa Tugrul GoktaşFazleen HattaUmit Yasar Pharmacogenetics 02 August 2015 Pages: 1223 - 1228
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves Jee-Eun ChungByung Chul ChangHye Sun Gwak Pharmacogenetics 11 August 2015 Pages: 1229 - 1236
An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe Hans C. EbbersJoris LangedijkMarie L. De Bruin Pharmacoepidemiology and Prescription Open access 25 July 2015 Pages: 1237 - 1244
Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication Helle Wallach-KildemoesEbba Holme Hansen Pharmacoepidemiology and Prescription 31 July 2015 Pages: 1245 - 1254
Majority of drug-related problems identified during medication review are not associated with STOPP/START criteria Sanne VerdoornHenk-Frans KwintMarcel L Bouvy Pharmacoepidemiology and Prescription Open access 07 August 2015 Pages: 1255 - 1262
Income differences in the type of antihypertensive medicines used in ambulatory settings in Finland: a register-based study Härkönen MirvaTimonen JohannaKatri Aaltonen Pharmacoepidemiology and Prescription 31 July 2015 Pages: 1263 - 1270
Anticholinergic burden in Parkinson’s disease inpatients Unax LertxundiArantxazu IslaJuan Medrano Pharmacoepidemiology and Prescription 09 August 2015 Pages: 1271 - 1277
Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery Caroline M J van KinschotNielka P. van ErpVincent O. Dezentjé Letter to the Editors 16 July 2015 Pages: 1279 - 1281
Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA) J. L. MontastrucV. RousseauH. Bagheri Letter to the Editors 22 July 2015 Pages: 1283 - 1284
Linezolid underexposure in a patient co-treated with venlafaxine Piergiorgio CojuttiMassimo CrapisFederico Pea Letter to the Editors 08 August 2015 Pages: 1285 - 1286